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Background: The reported reliability of core needle biopsy (CNB) is high in assessing thyroid nodules after
inconclusive fine-needle aspiration (FNA) attempts. However, first-line use of CNB for nodules considered at risk by
ultrasonography (US) has yet to be studied. The aim of this study were: 1) to evaluate the potential merit of using
CNB first-line instead of conventional FNA in thyroid nodules with suspicious ultrasonographic features; 2) to
compare CNB and FNA as a first-line diagnostic procedure in thyroid lesions at higher risk of cancer.
Methods: Seventy-seven patients with a suspicious-appearing, recently discovered solid thyroid nodule were
initially enrolled as study participants. No patients had undergone prior thyroid fine-needle aspiration/biopsy. Based
on study design, all patients were proposed to undergo CNB as first-line diagnostic aspiration, while those patients
refusing to do so underwent conventional FNA.
Results: Five patients refused the study, and a total of 31 and 41 thyroid nodules were subjected to CNB and FNA,
respectively. At follow-up, the overall rate of malignancy was of 80% (CNB, 77%; FNA, 83%). However, the diagnostic
accuracy of CNB (97%) was significantly (P < 0.05) higher than that of FNA (78%). In one benign lesion, CNB was
inconclusive. Four (12%) of the 34 cancers of the FNA group were not initially diagnosed because of false negative
(N = 1), indeterminate (N = 2) or not adequate (N = 1) samples.
Conclusions: CNB can reduce the false negative and inconclusive results of conventional FNA and should be
considered a first-line method in assessing solid thyroid nodules at high risk of malignancy.
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Ultrasound (US) examination is the standard method for
stratifying risk for malignancy in both palpable and non-
palpable thyroid lesions, thus determining the need for
fine-needle aspiration (FNA) [1,2]. A number of publica-
tions attest to the specific features by US and color
flow Doppler (CFD) that are suggestive of malignancy,* Correspondence: giuseppe.nigri@uniroma1.it
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unless otherwise stated.namely hypoechogenicity, irregular or blurred margins,
microcalcifications, taller shape, and vascular signals
[3,4]. In addition to conventional US, elastography is be-
lieved to improve the management of thyroid lesions,
increasing the sensitivity of US-CFD when done in tan-
dem [5]. As a consequence, cold nodules with the above
features qualify for biopsy [1,2].
Although FNA can accurately distinguish thyroid can-
cers from benign lesions, there are a number of limita-
tions [1,2]. The chief drawback is that up to 25 to 30%
of cytologic samplings are inconclusive (that is, indeter-
minate or inadequate), often necessitating diagnosticl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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malignant by histology, thus a means to further differen-
tiate benign and cancerous lesions is advantageous.
Moreover, many sources indicate that the falsenegative
rate of FNA cytology with respect to thyroid cancers is
not insignificant [6-8]. However, thyroid core needle bi-
opsy (CNB) has recently been cited as a reliable test
[9-14]. The microhistology of CNB samplings enables
diagnosis in a large percentage of thyroid lesions deemed
indeterminate or inadequate by FNA. The semi-
automated CNB needles used are of small caliber (20 to
22 gauge), allowing full access to both large and small
thyroid nodules with few complications and high patient
tolerability [15]. Although the popularity of CNB has
risen worldwide, this technique has primarily assumed a
lesser role in thyroid lesions diagnosis, reserved for in-
stances of inconclusive cytology. There are no data on
its use as a first-line diagnostic tool in thyroid nodules at
high risk of malignancy.
This study was designed to evaluate the potential
merit of using CNB first-line instead of conventional
FNA to assess thyroid nodules with suspicious US fea-
tures. Thyroid nodule diagnostic results with CNB were
compared with outcomes of patients subjected to FNA.
Methods
Patients
From September 2012 to April 2013, all patients refer-
ring to Ospedale Israelitico of Rome with a recently dis-
covered suspicious thyroid nodule were selected for this
study. None of the patients had undergone prior thyroid
nodule aspiration/biopsy. All nodules were found to be
solid at US and hot lesions were excluded. Seventy-
seven patients (females, 64; males, 13) granting informed
consent were initially enrolled as study participants. The
study design proposed that all patients undergo CNB as
first-line diagnostic aspiration, and those patients refus-
ing CNB were tested by conventional FNA.
Ultrasound examination
As in an earlier prospective multicenter study of ours
[5], US risk stratification was aligned with Society of Ra-
diologists in Ultrasound [16] and AACE/AME/ETA cri-
teria [1]. The pattern of vascular signals within nodules
was scrutinized by CFD and designated as absent, peri-
nodular, or intranodular [17]. Real-time elastography
(RTE) was also performed, ranking nodules as class I
(prevalence of red and green color), class II (green with
prevalence in more than 50% of the nodule), class III
(blue in at least 50% of nodule), or class IV (blue with
prevalence in at least 75% of nodule) [5]. To qualify as
an ‘at-risk’ nodule by US examination, at least two of the
following features were required: marked hypoechogeni-
city, microcalcifications, irregular margins, taller ratherthan wider shape, intranodular vascularization, and RTE
class III to IV.
In all patients, US, CFD, and RTE examinations were per-
formed prior to aspiration by an experienced endocrinolo-
gist, using an EsaoteMyLab system (Esaote, Genova, Italy)
with linear probe. Ultrasonographic evaluation of each nod-
ule was repeated by a second expert examiner. Any dis-
cordant cases were mutually resolved by the two physicians
for definitive classification. Before the study began, US
technique was standardized by the two operators for pro-
cedural reproducibility [5].
FNA and CNB procedures
Patients were instructed to refrain from anticoagulants
during the five days prior to FNA and CNB. Both biop-
sies were performed at Ospedale Israelitico of Rome by
the same experienced surgeon in freehand fashion under
US guidance. For FNA, a 23-gauge needle was utilized,
while for CNB a 21-gauge Menghini cutting needle (Bio-
mol, Hospital Service, Rome, Italy) was employed, as
previously described [14,15]. Two needle passes were
made for both biopsies. Before CNB, a local anesthetic
was administered.
Cytologic and microhistologic examination
Cytologic specimens were screened by an expert cytopa-
thologist, conforming to AACE/AME/ETA [1] as follows:
class 1 (inadequate), class 2 (benign), class 3 (indetermin-
ate), class 4 (suspicious of malignancy), or class 5
(malignant).
Formalin-fixed needle cores underwent automated pro-
cessing for embedding in paraffin, as we previously detailed
[14,15]. Serial sections at 4 μm were affixed to polarized
slides. A single H&E-stained slide was generated, and the
remainder were immunostained for galectin-3, cytokeratin-
19 and HBME-1 (Thermo Fisher Scientific, Fremont, CA,
USA), using a biotin-free peroxidase method. All specimens
were evaluated by an experienced pathologist.
All cytologic and microhistologic samples were also
reviewed by a second pathologist. In case of disagree-
ment, definitive reporting was achieved by mutual
consensus.
Follow-up
Final histologic examination was the ‘gold standard’ in all
patients. Thyroid tumor classification relied on the most re-
cent World Health Organization histologic criteria [18].
Statistical analysis
Comparison of frequency was made by chi-squared test
or Fisher exact test, as appropriate. Means and standard
deviations were compared by the Student’s t-test. Statis-
tical analysis was performed using Graph Pad Prism
(Graph Pad Software Inc, La Jolla, CA, USA).
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Five patients declined to participate in the study, and the
final series included 72 nodules (size 11.5 ± 4.8 mm)
from 72 patients (females, 60; males, 12; mean age, 50.4 ±
13.7 years). A proportion of these patients consented to
undergo CNB (N = 31), while the remainder refused CNB
and were tested via routine FNA (N= 41). Table 1 details
the US nodules characteristics of the two groups.CNB group
Mean size of the 31 nodules subjected to CNB was 12.3 ±
3.8 mm. Of these, 30 (96.8%) were diagnostic: 24 cancers
and 6 benign lesions. One nodule (3.2%) was found to
be inadequate. The histologic examination confirmed
cancer in all 24 cases (classic papillary cancers, 14; follicular
variant of papillary cancer, 9; medullary carcinoma, 1)
and benign lesions in the remaining 6 specimens
(nodular thyroiditis, 4; microfollicular hyperplasia, 2).
The inadequate CNB sampling proved to be microfollicular
hyperplasia (Figure 1).FNA group
Of the 41 nodules (mean size 11.2 ± 5.1 mm) subjected
to FNA, 33 (80.5%) were initially diagnostic (class 5, 17;
class 4, 13; class 2, 3). The other 8 (19.5%) were mostly
indeterminate, with the exception of one inadequate spe-
cimen (Figure 1). Histologic confirmation of cancer was
obtained for all patients with class 4 or 5 cytology. FNA
was repeated in patients with class 2: 2 nodules were be-
nign (class 2) with microfollicular hyperplasia at hist-
ology, while the other one was cancer (class 5) with
postsurgical follicular variant of papillary carcinoma
(Figure 2). The eight nodules with inconclusive (class 1
or class 3) results by FNA were selected for complemen-
tary CNB sampling. Of these, five were benign lesions
(nodular thyroiditis, four; microfollicular hyperplasia,
one) and three were considered malignant, as confirmedTable 1 Main ultrasound characteristics of 72 solid
nodules included in the study
CNB group FNA group P
Size (mm) 12.3 ± 3.8 11.2 ± 5.1 0.31
Marked hypoechogenicity 26 (82.9%) 37 (90.2%) 0.48
Taller shape 5 (16.1%) 7 (17.1%) 0.83
Microcalcifications 14 (45.2%) 21 (51.2%) 0.78
Intranodular vascularization 17 (54.8%) 20 (48.8%) 0.78
Score III to IV at elastography 26 (83.9%) 32 (78.0%) 0.75
More than two risk features 15 (48.4%) 17 (41.5%) 0.72
Legend: CNB, core needle biopsy; FNA, fine-needle aspiration. Marked
hypoechogenicity, solid hypoechoic nodule with no cystic areas. Taller shape, taller
than wide shaped nodule. Microcalcifications, hyperechoic punctuations <2 mm.
Intranodular vascularization, intralesional vascular signal. Score III to IV at
elastography, blue color in more than 50% of the nodule.after surgery. Histologic features of 34 cancers from the
FNA group are shown in Table 2.
Comparison of the results from the two groups
No significant difference was found in nodule size and US
characteristics between the two groups (Table 1). At follow-
up, the overall rate of malignancy in the 72 patients was
80.5% (CNB, 77.4%; FNA, 82.9%). Diagnostic accuracy was
significantly (P < 0.05) higher in CNB (30/31; 96.8%) than
in FNA (32/41, 78%) group. No false negatives were re-
corded in CNB samples. In the FNA series, 4 (12%) of the
34 cancers were not initially diagnosed (false negative, 1; in-
determinate, 2; not adequate, 1) and a 2.5% rate of false
negative (class 2) results was recorded (Figure 1). Similar to
our previous experiences [15,16], no complications were re-
corded after the biopsies.
Discussion
Ultrasonographic risk stratification is the standard
means of determining the need for biopsy in patients
with thyroid nodules. Although FNA is the most cost-
effective method of thyroid biopsy at present [1], a con-
siderable percentage of cytologic preparations are diag-
nostically inconclusive. Molecular or genetic markers
and clinical or instrumental features can be used to bol-
ster FNA outcomes [19-24] but diagnostic surgery is
often unavoidable [1,2,24]. CNB was introduced to bet-
ter assess these thyroid nodules, and this approach is
gaining momentum [9-14]. Unfortunately, its role has
been limited to a complementary use in patients with in-
conclusive FNA results. Data from previous studies indi-
cate that up to 98% of nodules indeterminate by FNA
are diagnosable by CNB, and the combination of CNB
and second-round FNA identifies 97% of nodules with
prior inadequate FNA [9-14]. Therefore, chances of tai-
loring the surgical approach and reducing unnecessary
surgery are substantial [25].
In the present study, our aim was to investigate the
potential role of CNB as a first-line technique instead of
conventional FNA for assessing thyroid nodules at risk
of cancer by ultrasonography. To date, this particular ap-
proach has not been studied. It is generally accepted that
the likelihood of malignancy rises if risk features are
identified in a thyroid nodule by US [1,2], and that FNA
should be repeated under these circumstances, regard-
less of a benign cytologic result [6-8]. Recently, the diag-
nostic utility of CNB was explored in sonographically
suspicious thyroid nodules with initially benign cytol-
ogies, exposing a 32% rate of cancer [26]; in agreement
with previous reports [9-15], CNB provided reliable
diagnostic accuracy, reducing the need for repetitive
FNA or diagnostic surgery.
Herein, we selected 72 patients with suspicious thyroid
nodules for either CNB or FNA as the first-line diagnostic
Figure 1 Study design and main results.
Table 2 Final histologic diagnosis of 34 cancers from
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nancy rate was recorded because patients were at risk for
cancer. Ultimately, CNB (97%) significantly outperformed
FNA (78%) in terms of diagnostic accuracy. FNA results
also failed to reflect four cancers with a 2.5% rate of false
negatives (class 2), and five other benign lesions were cyto-
logically indeterminate. Furthermore, there were no false
negatives by CNB, and only one benign nodule was inad-
equate at CNB sampling.
Thyroid cytology is recognized as accurate, but its lim-
itations with respect to misdiagnosis must be acknowl-
edged. Aside from a certain percentage of inconclusive
diagnoses by cytology demonstrated here (8/41, 19%),
the potential for false results also exists. False negatives
may be due poorly cellular aspirates or sampling error
[27], approaching 11% in large and cystic lesions [28].
Similarly, papillary cancer may be misclassified as be-
nign, owing to macrofollicular presentation in the ab-
sence of tell-tale cytologic alterations and architecturalFigure 2 Follicular variant of papillary carcinoma
(immunohistochemistry for CK19). Note the macrofollicular
pattern of the papillary neoplasm.atypia (microfollicular or papillary pattern). In a recent
paper, most false negatives were attributable to the fol-
licular variant of papillary cancer [29]. Importantly, it
must be emphasized that cancers not easily detected by
FNA have higher rates of vascular and capsular invasion,
increasing the odds of persistent disease [30]. On the
other hand, the cutting needles of CNB enable microhis-
tologic sampling of both large and small size thyroid
nodules, with a high degree of accuracy. Expanding on
our previous reports [9-14,26], we have shown for the
first time that CNB should be considered the first-line
approach in nodules defined at-risk by US to avoid false-
negative results and to reduce the reports found to bein-
conclusive by FNA.
Furthermore, patient tolerability of CNB during this




Class 1 1 Follicular variant of papillary carcinoma
Class 2 1 Follicular variant of papillary carcinoma
Class 3 2 Hürthle cell carcinoma (n = 1)
Follicular variant of papillary carcinoma
(n = 1)
Class 4 13 Classic papillary carcinoma (n = 4)
Follicular variant of papillary carcinoma
(n = 7)
Hürthle cell carcinoma (n = 2)
Class 5 17 Classic papillary carcinoma (n = 13)
Follicular variant of papillary carcinoma
(n = 3)
Columnar variant of papillary carcinoma
(n = 1)
Legend: class 1, inadequate;class 2, benign;class 3, indeterminate;class 4,
suspicious for malignancy;class 5, malignant.
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comfort level confirmed previous findings (data not
shown).
For clinical practice, based on our previous experience
and according to the present data, we were discouraged-
from repeating FNA after an initial inconclusive cyto-
logic report. In this circumstance, as well as in the
occurrence of recently discovered thyroid nodules de-
fined as ‘suspicious for malignancy’, CNB should be used.
This approach could avoid the ‘risk’ of false negative
FNA and a delay in diagnosing thyroid cancers.
Conclusions
In conclusion, our findings indicate a higher rate of diag-
nostic accuracy with first-line use of CNB than FNA for
assessing at-risk thyroid nodules identified by US. The
false negatives and inconclusive results of FNA may also
be reduced making CNB the preferred method in this
setting.
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